Source:http://linkedlifedata.com/resource/pubmed/id/11698275
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2001-11-7
|
| pubmed:abstractText |
One hundred nine patients with hematologic malignancies, undergoing bone marrow transplants (BMT) from unrelated donors, were randomized in 2 consecutive trials to receive or not to receive antithymocyte globulin (ATG) in the conditioning regimen, as follows: (A) 54 patients (median age, 28 years; 39% with advanced disease) were randomized to no ATG (n = 25) versus 7.5 mg/kg rabbit ATG (Thymoglobulin; Sangstat, Lyon, France) (n = 29); (B) 55 patients (median age, 31 years, 71% with advanced disease) were randomized to no ATG (n = 28) versus 15 mg/kg rabbit ATG (n = 27). Grade III-IV graft-versus-host disease (GVHD) was diagnosed in 36% versus 41% (P =.8) in the first and in 50% versus 11% (P =.001) in the second trial. Transplant-related mortality (TRM), relapse, and actuarial 3-year survival rates were comparable in both trials. In fact, despite the reduction of GVHD in the second trial, a higher risk for lethal infections (30% vs 7%; P =.02) was seen in the arm given 15 mg/kg ATG. Extensive chronic GVHD developed overall more frequently in patients given no ATG (62% vs 39%; P =.04), as confirmed by multivariate analysis (P =.03). Time to 50 x 10(9)/L platelets was comparable in the first trial (21 vs 24 days; P =.3) and delayed in the ATG arm in the second trial (23 vs 38 days; P =.02). These trials suggest that (1) 15 mg/kg ATG before BMT significantly reduces the risk for grade III-IV acute GVHD, (2) this does not translate to a reduction in TRM because of the increased risk for infections, and (3) though survival is unchanged, extensive chronic GVHD is significantly reduced in patients receiving ATG.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AlessandrinoP EPE,
pubmed-author:BacigalupoAA,
pubmed-author:BarbantiMM,
pubmed-author:BosiAA,
pubmed-author:BruniDD,
pubmed-author:BruzziPP,
pubmed-author:GuidiSS,
pubmed-author:LamparelliTT,
pubmed-author:OnetoRR,
pubmed-author:SacchiNN,
pubmed-author:Van LintM TMT,
pubmed-author:di BartolomeoPP
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
98
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2942-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11698275-Adolescent,
pubmed-meshheading:11698275-Adult,
pubmed-meshheading:11698275-Animals,
pubmed-meshheading:11698275-Antilymphocyte Serum,
pubmed-meshheading:11698275-Bone Marrow Transplantation,
pubmed-meshheading:11698275-Cause of Death,
pubmed-meshheading:11698275-Cyclosporine,
pubmed-meshheading:11698275-Disease-Free Survival,
pubmed-meshheading:11698275-Female,
pubmed-meshheading:11698275-Graft vs Host Disease,
pubmed-meshheading:11698275-Hematologic Neoplasms,
pubmed-meshheading:11698275-Humans,
pubmed-meshheading:11698275-Immunosuppressive Agents,
pubmed-meshheading:11698275-Infection Control,
pubmed-meshheading:11698275-Italy,
pubmed-meshheading:11698275-Life Tables,
pubmed-meshheading:11698275-Male,
pubmed-meshheading:11698275-Methotrexate,
pubmed-meshheading:11698275-Middle Aged,
pubmed-meshheading:11698275-Rabbits,
pubmed-meshheading:11698275-Survival Analysis,
pubmed-meshheading:11698275-T-Lymphocytes,
pubmed-meshheading:11698275-Transplantation, Homologous,
pubmed-meshheading:11698275-Transplantation Conditioning
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
|
| pubmed:affiliation |
Ospedale San Martino, Genova, Italy. apbacigalupo@smartino.ge.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|